Health Care · Pharmaceutical Preparations · Nasdaq · CIK 872589 · FYE Dec 31 · Prices AT CLOSE 2026-08-20 (USD) Last $826.64 · Day −1.69% · Mkt cap $79.0B · P/E (FY) 20.3× · 1Y +40.4% · Off 52W high −2.2% · Vol (1Y) 33.7% Price2023-08-21 → 2026-08-20 REGN close: $844 on 2023-08-21 to $827 on 2026-08-20. Split-adj closes · 240 of 6,695 · price returnⓘ At a glance | Short interest3.6% of sh out | | Days to cover3.9d | | 13F net flow (QoQ)+0.84% | | Top-10 13F concentration46.0% | | Next report (est.)2026-10-29 |
SI 2026-07-31 · 13F 2026-Q1ⓘ Key fundamentalsFY 2025 | P/E (FY)20.3× | | Sales (TTM)$15.53B | | Earnings (TTM)$4.33B | | ROE14.9% | | Net margin31.4% | | ROIC10.5% | | Debt / equity0.06× | | Total debt / EBITDA0.48× | | EPS growth 3Y2.8% | | Sales growth 3Y5.6% |
FY ratios · TTM sales/earnings (USD)ⓘ Trailing returns | YTD+7.4% | | 1Y+40.4% | | 3Y−1.3% | | 5Y+25.7% | | 10Y+99.1% | | Since incept. (ann.)+17.2% |
Total return · from 2000-01-03ⓘ Risk | Ann. volatility (1Y)33.7% | | Ann. volatility (3Y)31.3% | | Sharpe (1Y)1.29 | | Sharpe (3Y)0.14 | | Max drawdown (1Y)−25.9% | | Max drawdown (3Y)−59.7% | | Beta (3Y vs SPY)0.07 |
Daily returns, ann.ⓘ Top institutional holders13F 2026-Q1 | Manager | Shares | Value | % sh out | QoQ |
|---|
| BlackRock, Inc. | 8.9M | $6.9B | 8.61% | +2.4% | | VANGUARD CAPITAL MANAGEMENT LLC | 6.7M | $5.1B | 6.40% | new | | STATE STREET CORP | 4.7M | $3.6B | 4.49% | +0.1% | | Dodge & Cox | 4.5M | $3.4B | 4.29% | −3.0% | | JPMORGAN CHASE & CO | 4.3M | $3.2B | 4.15% | +9.4% | | FRANKLIN RESOURCES INC | 2.7M | $2.1B | 2.62% | +6.3% | | GEODE CAPITAL MANAGEMENT, LLC | 2.6M | $2.0B | 2.51% | +3.5% | | PRICE T ROWE ASSOCIATES INC /MD/ | 2.2M | $1.7B | 2.10% | +11.7% |
Δ vs 2025-Q4ⓘ Latest reported quarterslast report 2026-07-30 | Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|
| 2026-06-30 | 2026-07-30 | $12.23 | −4.5% | $4.29B | +16.7% | | 2026-03-31 | 2026-04-29 | $6.75 | −7.2% | $3.61B | +19.0% | | 2025-12-31 | 2026-01-30 | — | — | $3.88B | +2.5% | | 2025-09-30 | 2025-10-28 | $13.62 | +18.0% | $3.75B | +0.9% |
As-reported XBRL · next 2026-10-29 est.ⓘ Segment mixFY2025 (ended Dec 2025) Collaboration Revenue 46% · Product 40% · LIBTAYONet Product Sales 9% · Product And Service Other 4% · Other Products 0% product & service · TAGGED revenueⓘ Basis & disclosures - EOD closes · nothing imputed or averaged · absent “—”
- As-of differs by block · 13F = US long, 45+d lag, LOWER bound
- Not investment advice · no recommendation, price target or solicitation
- EDGAR + foreign registers · marketstack (licensed EOD) · spzco.com/methodology
| 
